title: Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides.
abstract: Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular- targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimetry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing (90)Y, (188)Re, (166)Ho, (149)Pm, (64)Cu, and (177)Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for (90)Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for (90)Y to 1% for (177)Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.
authors.affiliation: Nuclear Science and Engineering Institute, University of Missouri, Columbia, MO 65211, USA. MillerW@missouri.edu
authors.forename: William H
authors.initials: WH
authors.lastname: Miller
authors.forename: Christine
authors.initials: C
authors.lastname: Hartmann-Siantar
authors.forename: Darrell
authors.initials: D
authors.lastname: Fisher
authors.forename: Marie-Anne
authors.initials: MA
authors.lastname: Descalle
authors.forename: Tom
authors.initials: T
authors.lastname: Daly
authors.forename: Joerg
authors.initials: J
authors.lastname: Lehmann
authors.forename: Michael R
authors.initials: MR
authors.lastname: Lewis
authors.forename: Timothy
authors.initials: T
authors.lastname: Hoffman
authors.forename: Jeff
authors.initials: J
authors.lastname: Smith
authors.forename: Peter D
authors.initials: PD
authors.lastname: Situ
authors.forename: Wynn A
authors.initials: WA
authors.lastname: Volkert
mesh_terms: D000818:Animals; D003301:Copper Radioisotopes / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006695:Holmium / Q000627:therapeutic use*; D008187:Lutetium / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D015233:Models, Statistical; D008962:Models, Theoretical; D011399:Promethium / Q000627:therapeutic use*; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000627:therapeutic use*; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D012211:Rhenium / Q000627:therapeutic use*; D014018:Tissue Distribution; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D003301:Copper Radioisotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D008187:Lutetium; D012211:Rhenium; D006695:Holmium; D011399:Promethium